Advertisement

Archive for Thursday, September 23, 2010

Area pharmaceutical firm signs deal on developing treatment for dogs with cancer

September 23, 2010

Advertisement

An area pharmaceutical firm has signed a deal with the University of Missouri in hopes of developing a drug to treat cancer in dogs.

Lawrence-based CritiTech Inc. has reached an agreement with the Missouri College of Veterinary Medicine to study whether its drug Nanotax can be used in canines.

CritiTech, 1321 Wakarusa Drive, has long been developing Nanotax to treat cancer in human patients. But the company also believes the drug has potential for veterinary use. The deal with the University of Missouri will allow veterinarians to begin testing different dosage levels on dogs.

CritiTech leaders expect the study to take about 18 months to complete.

Comments

frank mcguinness 3 years, 12 months ago

Because canine cancer is a priority in america right now, particularly when we can barely cure human cancers.

0

parrothead8 3 years, 12 months ago

The story clearly states that the drug was developed for humans first. What's wrong with trying to see if it helps another species?

0

Sigmund 3 years, 12 months ago

When the society collapses under its own weight, I am going to be glad I have a large cancer free dog herd to rely on that was given a drug which was tested on humans BEFORE testing it on dogs. How cruel would that have been?

0

Richard Heckler 3 years, 12 months ago

Does Nanotax help humans?

Does it cure cancer? Or is it just another very expensive treatment that does what?

Nanotax® Phase I Trial in Peritoneal Cancers (National Cancer Institute description)

Nanotax is currently enrolling patients in a Phase 1 Clinical Trial for peritoneal cancers including: ovarian, mullerian tumors, gastrointestinal or metastatic tumors to the peritoneum. This trial will enroll approximately 24 patients who have failed all other therapies available.

The study involves surgical placement of a peritoneal port allowing for direct delivery of Nanotax to the peritoneal cavity. The study is currently open at The University of Kansas Cancer Center located in Westwood, Kansas.

Paclitaxel is a commonly used chemotherapy drug that is known to have serious side effects. The side effects are due in large part to the solvent that Paclitaxel must be mixed with in order to be given to a patient. Nanotax is a reformulation of Paclitaxel that allows it to be mixed with water and then administered to patients.

0

Tony Kisner 3 years, 12 months ago

Merill - I not sure I know of too many treatments for cancer that are a walk in the park. Are you working on something in the basement to cure cancer with no side effects which by the way you will just give away for free, or just lobbing bricks?

Lots of haters.

0

Commenting has been disabled for this item.